Correlation analysis of serum AAG/LDH and BLa levels with the prognosis of severe pneumonia complicated with shock
Serum AAG/LDH and BLa levels in severe pneumonia with shock
Abstract
Objective This study aimed to explore the relationships between serum α1-acid glycoprotein (AAG), lactate dehydrogenase (LDH), and blood lactate (BLa) levels and the severity and prognosis of severe pneumonia (SP) complicated with shock in elderly patients to provide useful references for clinical diagnosis and treatment.
Methods From May 2024 to July 2025, 364 elderly patients with SP combined with shock who were admitted to our hospital composed the SP combined with shock group. Depending on their severity, the patients were split into low-, medium-, and high-risk groupings. A good prognosis group and a bad prognosis group were subsequently assigned to the patients based on the follow-up data. An additional 364 elderly patients with SP who did not experience shock and were admitted to our hospital during that time frame were chosen to be part of the SP group. Following measurements of each research participant's serum levels of AAG, LDH, and BLa, the AAG/LDH ratio was calculated. APACHE II (Acute Physiology and Chronic Health Evaluation II) and CPIS (clinical pulmonary infection) scores, and the AAG, LDH, and BLa levels of elderly patients with SP combined with shock were correlated with each other using Spearman correlation analysis. Using multivariate logistic regression analysis, the factors influencing the progression to high risk and poor prognosis in elderly patients with SP accompanied with shock were investigated. A receiver operating characteristic (ROC) curve was used to assess the predictive power of serum AAG/LDH and BLa for the prognosis of elderly individuals with SP accompanied with shock.
Results While the SP group's serum LDH level was lower than the SP group's, the SP combined with shock group's serum AAG and BLa levels and AAG/LDH ratios were higher. Each of these variations was statistically significant (P<0.05). The low-risk category had 120 patients, the medium-risk subgroup had 158, and the high-risk segment had 86. While the low-risk subgroup's serum LDH level was higher than that of the medium-risk and high-risk subgroups (P<0.05), the low-risk subgroup's serum AAG levels, BLa levels, AAG/LDH ratios, APACHE II scores, and CPIS scores were lower. The medium-risk subgroup's blood AAG, BLa, AAG/LDH ratio, APACHE II score, and CPIS score were all lower than the high-risk subgroup's, but the high-risk subgroup's serum LDH level was greater (P<0.05). Spearman correlation analysis revealed a negative correlation (P<0.05) between the serum LDH level and the APACHE II score and CPIS score, and a positive correlation (P<0.05) between the serum AAG level, BLa level, AAG/LDH ratio, and APACHE II score in elderly patients with SP and shock. There were 94 patients with poor prognoses and 270 patients in the group with good prognoses. While the good prognosis group had a greater serum LDH level than the bad prognosis group, the good prognosis group had lower serum AAG and BLa levels, a lower AAG/LDH ratio, a lower APACHE II score, and a lower CPIS score (P<0.05). Multivariate logistic regression analysis showed that elevated blood AAG/LDH and BLa levels were independent risk variables for progression to high risk and poor prognosis in elderly SP combined with shock patients (P<0.05). In predicting poor prognosis in older patients with SP and shock, the areas under the curve (AUCs) for blood AAG/LDH and BLa were 0.841 and 0.823, respectively, according to the results of the ROC curve study. When predicting poor outcome in elderly patients with SP and shock, the combined AUC of AAG/LDH and BLa was 0.934, higher than the AUC of each sign alone (P<0.05).
Conclusion In elderly patients with SP complicated by shock, the levels of serum AAG/LDH and BLa show abnormal changes, which are closely related to the severity of the disease and patient prognosis. The combination of serum AAG/LDH and BLa for predicting the prognosis of elderly patients with SP complicated by shock has relatively high value.
References
He L, Wang J, Ning Y, Pan K, Chen Y, Lu J, Wang D. Severe pneumonia combined with septic shock caused by community-acquired methicillin-resistant Staphylococcus aureus treated with veno-venous ECMO: A case report. Medicine (Baltimore). 2025 Mar 28;104(13):e41627. doi: 10.1097/MD.0000000000041627. PMID: 40153769; PMCID: PMC11957642.
Tan J, Huang B, Luo S, Li R, Hou J, Zhang R, Wang L, Liu Y, Li F, Feng J. A rare case of severe pneumonia combined with septic shock caused by Nocardia amamiensis. Travel Med Infect Dis. 2024 May-Jun;59:102710. doi: 10.1016/j.tmaid.2024.102710. Epub 2024 Mar 11. PMID: 38467232.
Zhang Y, Guo R, Wang L, Hu J. Association between lactate-to-albumin ratio and 28-day ICU mortality in pediatric severe pneumonia patients. PLoS One. 2025 Sep 12;20(9):e0331486. doi: 10.1371/journal.pone.0331486. PMID: 40938884; PMCID: PMC12431254.
Wang J, Wang R, Zhou Y, Ma Y, Xiong C. The relationship between lactate dehydrogenase and Apolipoprotein A1 levels in patients with severe pneumonia. J Med Biochem. 2024 Apr 23;43(2):290-298. doi: 10.5937/jomb0-45782. PMID: 38699695; PMCID: PMC11062332.
Jankovic J, Stjepanovic M, Maric N, Belic S. Gender differences in correlation of biochemical parameters with the severity of covid pneumonia and the need for oxygen/mechanical support. J Med Biochem. 2025 Mar 21;44(2):250-255. doi: 10.5937/jomb0-49377. PMID: 40386524; PMCID: PMC12085188.
Trabelsi B, Ghorbel S, Ben Rabeh R, Bouassida M, Ben Ali M. α1-acid glycoprotein in the early diagnosis of pneumonia complicating severe blunt chest trauma. Tunis Med. 2023 Oct 5;101(10):756-758. English. PMID: 38465756; PMCID: PMC11261490.
Huang L, Zhang R, Ji J, Long F, Wang Y, Lu J, Xu G, Sun Y. Hypersensitive α1-acid glycoprotein-albumin ratio is associated with stroke-associated pneumonia and early clinical outcomes in patients with acute ischemic stroke. Brain Behav. 2022 Jul;12(7):e2675. doi: 10.1002/brb3.2675. Epub 2022 Jun 24. PMID: 35748095; PMCID: PMC9304827.
Yadav RK, Kumar D, Gupta A, Sharma P. α1-acid glycoprotein and procalcitonin: As predictor biomarkers of severity and outcome in children with community-acquired pneumonia. Trop Doct. 2024 Jul;54(3):262-267. doi: 10.1177/00494755241250371. Epub 2024 May 2. PMID: 38693837.
Ishida H, Fukutomi T, Taniyama Y, Sato C, Okamoto H, Ozawa Y, Ando R, Shinozaki Y, Unno M, Kamei T. Serum α1-acid glycoprotein and procalcitonin levels in patients with pneumonia and anastomotic leakage in the postoperative period after esophagectomy. Gen Thorac Cardiovasc Surg. 2024 Nov;72(11):746-751. doi: 10.1007/s11748-024-02065-3. Epub 2024 Jul 29. PMID: 39073695.
Reccardini N, Confalonieri M, Ruaro B, Confalonieri P, Da Re B, Rocca A, Salton F. Early α1-acid glycoprotein reduction predicts survival in COVID-19 severe pneumonia treated with glucocorticoids. BMC Pulm Med. 2025 Sep 30;25(1):436. doi: 10.1186/s12890-025-03874-9. PMID: 41029298; PMCID: PMC12486572.
Che K, Zeng Z, Hong C, Peng D, Liu A, He Y. Association between serum α1-acid glycoprotein (CRP) and Omicron variant COVID-19 pneumonia in cancer patients: A multicenter cross-sectional study at the end of 2022 in China. Medicine (Baltimore). 2024 Jan 12;103(2):e36965. doi: 10.1097/MD.0000000000036965. PMID: 38215120; PMCID: PMC10783274.
Zhao T, Liu Y, Jia H, Wang D, Du M, Wang W. The significance of serum sST2 and cfDNA in children with severe pneumonia complicated by myocardial damage. J Med Biochem. 2025 Mar 21;44(2):264-268. doi: 10.5937/jomb0-51197. PMID: 40386513; PMCID: PMC12085171.
Ding F, Han L, Yin D, Zhou Y, Ji Y, Zhang P, Wu W, Chen J, Wang Z, Fan X, Zhang G, Zhang M. Development and validation of a simple tool composed of items on dyspnea, respiration rates, and α1-acid glycoprotein for pneumonia prediction among acute febrile respiratory illness patients in primary care settings. BMC Med. 2022 Oct 18;20(1):360. doi: 10.1186/s12916-022-02552-5. PMID: 36253753; PMCID: PMC9576309.
Pan T, Guo X, Yang D, Ding J, Chen C. Expression and significance of procalcitonin, leukotriene B4, serum amyloid A, and α1-acid glycoprotein in children with different types of pneumonia: An observational study. Medicine (Baltimore). 2024 May 10;103(19):e37817. doi: 10.1097/MD.0000000000037817. PMID: 38728486; PMCID: PMC11081565.
Yu R, Yan T, He J, Hu Y, Tang H. Clinical efficacy of combined detection of serum procalcitonin and α1-acid glycoprotein in early differential diagnosis of bacterial and viral pneumonia and analysis of related inflammatory response mechanisms. Biomark Med. 2025 Aug;19(15):657-666. doi: 10.1080/17520363.2025.2538428. Epub 2025 Jul 31. PMID: 40742025; PMCID: PMC12344818.
Mulyana R, Syafrita Y, Ali H, Murni AW. The Role of High Sensitivity α1-acid glycoprotein to Predict Delirium Persistence in Elderly Patients with Pneumonia: A Prospective Cohort Study. Acta Med Indones. 2022 Jul;54(3):414-418. PMID: 36156477.
Song X, Zhou N, Lu S, Gu C, Qiao X. New-generation tetracyclines for severe macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a retrospective analysis. BMC Infect Dis. 2024 Oct 16;24(1):1166. doi: 10.1186/s12879-024-10070-3. PMID: 39407159; PMCID: PMC11481790.
Yang S, Lu S, Guo Y, Luan W, Liu J, Wang L. A comparative study of general and severe mycoplasma pneumoniae pneumonia in children. BMC Infect Dis. 2024 Apr 26;24(1):449. doi: 10.1186/s12879-024-09340-x. PMID: 38671341; PMCID: PMC11046970.
Jiang Y, Huang X, Zhou H, Wang M, Wang S, Ren X, He G, Xu J, Wang Q, Dai M, Xiong Y, Zhong L, He X, Deng X, Pan Y, Xu Y, Cai H, Jin S, Wang H, Huang L. Clinical Characteristics and Prognosis of Patients With Severe Pneumonia With Pneumocystis jirovecii Colonization: A Multicenter, Retrospective Study. Chest. 2025 Jan;167(1):54-66. doi: 10.1016/j.chest.2024.07.140. Epub 2024 Jul 23. PMID: 39053646.
Feng S, Wang F, Wu W, Li Y, Chen C, Li J, Cao M, Peng L, Zhang P, Wang F. Analysis of multiple organ function damage in patients with severe COVID-19 pneumonia. J Med Biochem. 2023 Aug 25;42(3):444-453. doi: 10.5937/jomb0-41502. PMID: 37790212; PMCID: PMC10543486.
Huang SS, Qiu JY, Li SP, Ma YQ, He J, Han LN, Jiao LL, Xu C, Mao YM, Zhang YM. Microbial signatures predictive of short-term prognosis in severe pneumonia. Front Cell Infect Microbiol. 2024 Aug 2;14:1397717. doi: 10.3389/fcimb.2024.1397717. PMID: 39157177; PMCID: PMC11327560.
Liu J, Yang Z. A systematic review and meta-analysis of the efficacy and safety of glucocorticoids in the treatment of severe pneumonia. Clinics (Sao Paulo). 2025 Apr 23;80:100630. doi: 10.1016/j.clinsp.2025.100630. PMID: 40273494; PMCID: PMC12051649.
Li H, Duan S, Li L, Zhao G, Wei L, Zhang B, Ma Y, Wu MX, Mao Y, Lu M. Bio-Responsive Sliver Peroxide-Nanocarrier Serves as Broad-Spectrum Metallo-β-lactamase Inhibitor for Combating Severe Pneumonia. Adv Mater. 2024 Mar;36(11):e2310532. doi: 10.1002/adma.202310532. Epub 2023 Dec 20. PMID: 38095435.
Cao S, Liu L, Yang L, Li H, Zhu R, Yu G, Jiao N, Wu D. Assessing severe pneumonia risk in children via clinical prognostic model based on laboratory markers. Int Immunopharmacol. 2025 Apr 4;151:114317. doi: 10.1016/j.intimp.2025.114317. Epub 2025 Feb 20. PMID: 39983420.
Eriksson M, Lipcsey M, Ilboudo Y, Yoshiji S, Richards B, Hultström M. Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study. Physiol Genomics. 2024 May 1;56(5):409-416. doi: 10.1152/physiolgenomics.00145.2023. Epub 2024 Feb 19. PMID: 38369967.
Cao Y, Wang F. LncRNA RP11-773H22.4 is upregulated in severe pneumonia and may be a diagnostic and prognostic marker for severe pneumonia. Ann Biol Clin (Paris). 2024 Jun 5;82(2):187-199. doi: 10.1684/abc.2024.1886. PMID: 38702934.
Yusufu A, Xie Y, Shi Y, Jiang W, Hu J, Lv W, Ding X, Teng J, Shen B, Bi J, Zou J, Xu J. Early goal-directed renal replacement therapy in severe pneumonia associated acute kidney injury. Ren Fail. 2024 Dec;46(2):2392844. doi: 10.1080/0886022X.2024.2392844. Epub 2024 Sep 4. PMID: 39229916; PMCID: PMC11376310.
Müller-Plathe M, Osmanodja B, Barthel G, Budde K, Eckardt KU, Kolditz M, Witzenrath M. Validation of risk scores for prediction of severe pneumonia in kidney transplant recipients hospitalized with community-acquired pneumonia. Infection. 2024 Apr;52(2):447-459. doi: 10.1007/s15010-023-02101-z. Epub 2023 Nov 20. PMID: 37985643; PMCID: PMC10954831.
Zhu M, Lu Z, Liao X, Liang Q, Xu C, Luo X, Li J. Clinical value of dysregulated miR-125b-5p in severe pneumonia children. BMC Immunol. 2025 Apr 12;26(1):31. doi: 10.1186/s12865-025-00707-6. PMID: 40221643; PMCID: PMC11993971.
Liang Y, Li Y, Zhang K, Jia M, Xie K, Jing P, Zhao P, Wang H. Qingfei Jiedu Huatan Formula inhibits NLRP3 inflammasome activation to attenuates inflammation and pyroptosis in severe pneumonia: Integrating experimental verification, network pharmacology and transcriptomics. J Ethnopharmacol. 2025 Mar 13;343:119449. doi: 10.1016/j.jep.2025.119449. Epub 2025 Feb 11. PMID: 39947373.
Xing ZC, Guo HZ, Zhen P, Ao T, Hu M. Clinical application of metagenomic next-generation sequencing in etiologic diagnosis of severe pneumonia in adults. Front Cell Infect Microbiol. 2025 Apr 28;15:1561468. doi: 10.3389/fcimb.2025.1561468. PMID: 40357399; PMCID: PMC12066783.
Copyright (c) 2026 Jie Yang, Jia Li, Feng Tang, Mengjuan Wu, Zhiqiang Wang, Ziqi Song
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.